Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [1] Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Roehrig, Ute F.
    Majjigapu, Somi Reddy
    Vogel, Pierre
    Zoete, Vincent
    Michiein, Olivier
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (24) : 9421 - 9437
  • [2] Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Wang, Xiu-Xiu
    Sun, Si-Yu
    Dong, Qing-Qing
    Wu, Xiao-Xiang
    Tang, Wei
    Xing, Ya-Qun
    MEDCHEMCOMM, 2019, 10 (10) : 1740 - 1754
  • [3] Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
    Sari, Suat
    Tomek, Petr
    Leung, Euphemia
    Reynisson, Johannes
    MOLECULES, 2019, 24 (23):
  • [4] A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Xu, Haojie
    Song, Yunlong
    Yang, Qing
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (08) : 714 - 717
  • [5] Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
    Fang, Kun
    Dong, Guoqiang
    Li, Yu
    He, Shipeng
    Wu, Ying
    Wu, Shanchao
    Wang, Wei
    Sheng, Chunquan
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 312 - 317
  • [6] Discovery of novel and potent inhibitors of indoleamine-2,3-dioxygenase (IDO1) for cancer immunotherapy
    Liu, Shengyang
    Tao, Taoliangshan
    Liang, Yue
    Guo, Hongli
    Ye, Xiaogang
    Wu, Zhiheng
    Bao, Fang
    Yang, Heping
    Cai, Yaxian
    Yang, Gangjing
    Wang, Longsheng
    Liu, Fang
    Fu, Guangliang
    Liu, Xiaolei
    Du, Jiangang
    Qin, Ping
    Ma, Yuanfei
    Zhu, Panhu
    Yu, Yajun
    Ma, Chen
    Wang, Pei
    Zhao, Liping
    Wang, Yuxun
    Gao, Daxin
    Li, Qun
    CANCER RESEARCH, 2016, 76
  • [7] Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
    Xu, Xi
    Ren, Jie
    Ma, Yinghe
    Liu, Hongting
    Rong, Quanjin
    Feng, Yifan
    Wang, Yameng
    Cheng, Yu
    Ge, Ruijia
    Li, Zhiyu
    Bian, Jinlei
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 250 - 263
  • [8] Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Rohrig, Ute F.
    Majjigapu, Somi Reddy
    Reynaud, Aline
    Pojer, Florence
    Dilek, Nahzli
    Reichenbach, Patrick
    Ascencao, Kelly
    Irving, Melita
    Coukos, George
    Vogel, Pierre
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (04) : 2205 - 2227
  • [9] Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Rohrig, Ute F.
    Reynaud, Aline
    Majjigapu, Somi Reddy
    Vogel, Pierre
    Pojer, Florence
    Zoete, Vincent
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (19) : 8784 - 8795
  • [10] Development of 2" generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors
    Pesnot, Thomas
    Mahale, Sachin
    MacFaul, Philip
    Maclean, John
    Phillips, Caroline
    Bingham, Matilda
    Eagle, Catherine
    Kelly, James
    Thippeswamy, Abhijith
    Armitage, Simon
    Grisin, Aleksandr
    Aiken, Sheenagh
    Cartwright, Lucy
    Armer, Richard
    CANCER RESEARCH, 2017, 77